Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dornan

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The Journal of Biological Chemistry|April 2, 2002
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivoHarumi Shimizu, Lindsay R Burch, Amanda J Smith, et al.
Plos One|June 19, 2013
miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancerMichael S Hwang, Nancy Yu, Susanna Y Stinson, et al.
BMC Cancer|November 23, 2013
Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controlsNicholas Willumsen, Cecilie L Bager, Diana J Leeming, et al.
Nature|April 23, 2004
The ubiquitin ligase COP1 is a critical negative regulator of p53David Dornan, Ingrid Wertz, Harumi Shimizu, et al.
Cancer Medicine|July 22, 2014
Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancerNicholas Willumsen, Cecilie L Bager, Diana J Leeming, et al.
Cancer Research|October 20, 2004
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomasDavid Dornan, Sheila Bheddah, Kim Newton, et al.
BMC Genomics|September 25, 2013
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they controlEmanuele de Rinaldis, Patrycja Gazinska, Anca Mera, et al.
Haematologica|January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneDaniel O Persky, David Dornan, Bryan H Goldman, et al.
Nature|December 22, 2009
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survivalMartin Schwickart, Xiaodong Huang, Jennie R Lill, et al.
The Journal of Clinical Investigation|April 22, 2009
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceJing Qing, Xiangnan Du, Yongmei Chen, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|April 2, 2002
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivoHarumi Shimizu, Lindsay R Burch, Amanda J Smith, et al.
Plos One|June 19, 2013
miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancerMichael S Hwang, Nancy Yu, Susanna Y Stinson, et al.
BMC Cancer|November 23, 2013
Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controlsNicholas Willumsen, Cecilie L Bager, Diana J Leeming, et al.
Nature|April 23, 2004
The ubiquitin ligase COP1 is a critical negative regulator of p53David Dornan, Ingrid Wertz, Harumi Shimizu, et al.
Cancer Medicine|July 22, 2014
Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancerNicholas Willumsen, Cecilie L Bager, Diana J Leeming, et al.
Cancer Research|October 20, 2004
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomasDavid Dornan, Sheila Bheddah, Kim Newton, et al.
BMC Genomics|September 25, 2013
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they controlEmanuele de Rinaldis, Patrycja Gazinska, Anca Mera, et al.
Haematologica|January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneDaniel O Persky, David Dornan, Bryan H Goldman, et al.
Nature|December 22, 2009
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survivalMartin Schwickart, Xiaodong Huang, Jennie R Lill, et al.
The Journal of Clinical Investigation|April 22, 2009
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceJing Qing, Xiangnan Du, Yongmei Chen, et al.
Pageof 3